Targovax ASA
The 0RIS-LN stock trades on London Stock Exchange
Company Description
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and thereby bring benefit to cancer patients with few available treatment alternatives. Targovax is assessing its product candidates in different cancer indications, including melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable safety and tolerability profile.
Drug Pipeline
Source: Targovax ASA - 20220906
Asset
Indication
Pre-Clinical
Ph1
Ph2
Ph3
Reg/Com
Phase
Mutant KRAS immunotherapy
Multiple Myeloma
Phase 1
ONCOS-102
Colorectal Cancer
Phase 2
Melanoma
Phase 2
Mesothelioma
Phase 2
0 Comments on 0RIS-LN stock
Newest
Conversation